Key result
Ces3/Tgh(-/-) mice with deficient VLDL production exhibited attenuated plasma lipids and reduced tumor weight, demonstrating that tumor-induced hyperlipidemia supports tumor growth.
Population
Syngeneic tumor graft model using BCR-Abl-transformed precursor B cell tumors in mice
Comparison
Carboxylesterase3/triacylglycerol hydrolase… vs Wild-type mice
Design
Preclinical
Authors
Loading...
Hyperlipidemia may promote tumors in this model; leaves open whether VLDL inhibition merits human cancer trials.
Tumor-induced hyperlipidemia promotes tumor growth by reprogramming hepatic lipoprotein homeostasis, a process that can be attenuated by inhibiting VLDL production.
Huang et al. (2016) studied Tumor-induced hyperlipidemia. Ces3/TGH knockout vs. Wild-type mice was evaluated on Tumor weight and plasma lipid levels. Ces3/Tgh(-/-) mice with deficient VLDL production exhibited attenuated plasma lipids and reduced tumor weight, demonstrating that tumor-induced hyperlipidemia supports tumor growth.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: